Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35258841/
doi: 10.1007/s13300-022-01226-y. Online ahead of print. 1 Clinical Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Zaloška 7, 1000, Ljubljana, Slovenia. [email protected]. 2 Medical Faculty, University of...
Discussion: This is the first study to investigate the direct and indirect anti-atherosclerotic mechanisms of oral semaglutide. The results are expected to confirm the position of oral semaglutide in the multifactorial management of T2D with an emphasis on cardiovascular disease prevention.
Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice
Source : https://www.clinicaltherapeutics.com/article/S0149-2918(22)00052-2/fulltext
Greater medication adherence and persistence have been associated with improved glycemic control in patients with type 2 diabetes mellitus. This study compared adherence, persistence, and treatment patterns among patients naïve...
Implications: At both 6M and 12M follow-up, dulaglutide initiators had significantly greater adherence and greater persistence compared with matched semaglutide initiators.
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
Source : https://www.sciencedirect.com/science/article/abs/pii/S1871402122000418?via=ihub
GLP-1 receptor agonists are most commonly associated with gastrointestinal problems, particularly pancreatitis. * Exenatide and liraglutide caused maximum ADRs, whereas albiglutide and lixisenatide caused minimum ADRs. * Renal, dermatologic, hematologic,...
Conclusion: Gastrointestinal problems, particularly pancreatitis was the more frequently reported adverse drug reaction associated with GLP-1 agonist. The most adverse drug reactions were observed with liraglutide and exenatide.
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35226299/
Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is...
Relevance: This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.
Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents
Source : https://www.sciencedirect.com/science/article/abs/pii/S0223523422001167?via=ihub
Novel GLP-1R/CCK-1R co-agonists derivatized from the peptide backbone of xGLP-1. * 2a and 2c exhibited potent and selective GLP-1R and CCK-1R activation potency. * 2a and 2c showed prominent hypoglycemic...
/>
Conclusion: These preclinical studies suggest that the pharmacological effects of CCK-1 and GLP-1 pathways can be harnessed in a single fusion peptide, yielding a promising combination therapy strategy for treating metabolic disorders.